

References

REFERENCES

- Anthony, K.C., Leaker, M., Burrows, F., et al. (1997):** Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass. *Thromb.Haemost.* 77: 270-77.
- Bartha, K., Brisson, C., Archipoff, G., et al. (1993):** Thrombin regulates tissue factor and thrombomodulin mRNA levels and activities. *J.Biol.Chem.* 268:421-28.
- Beresford, C. and Owen, M. (1990):** Antithrombin III. *Int.J.Biochem.* 22:121-28.
- Bithell, T.C. (1993):** Wintrobe's Clinical Hematology, 9th Edition, Febiger Co., Philadelphia, London. Pages 518 & 578.
- Boldt, J., Kling, D., Bormann, B. et al. (1990):** Blood conservation in cardiac operations. *J.Thorac.Cardiovasc.Surg.* 97:832-40.
- Boldt, J., Knothe, C., Welters, I. et al. (1996):** Normothermic versus hypothermic cardiopulmonary bypass: do changes in coagulation differ? *Ann.Thorac.Surg.* 62:130-5.
- Boldt, J., Zickmann, B., Herold, C. et al. (1991):** Blood conservation techniques and platelet function in cardiac surgery. *Anaesthesiology* 45:426.
- Bom, V., Hinsbergh, V., Reinalda, H., and Bertina, R. (1992):** Extrinsic activation of human coagulation factors IX and X on the endothelial surface. *Thromb.Haemost.* 66:283-91.
- Borne, P., Laurent, O., Guido, T. et al. (1997):** Factor XI activation by meizothrombin. *Thromb.Haemost.* 78:834-9.

References

- Borne, P., Meyers, J. and Bouma, B. (1995):** Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. *Blood* **86**:3035-42.
- Carlos, T.M. (1994):** Leukocyte-endothelial adhesion molecules. *Blood* **84**:2068-101.
- Cavari, S. and Vannucchi, S. (1993):** Glycosaminoglycans exposed on the endothelial cell surface. *FEBS Lett* **323**:155-61.
- Christopher, P.J. (1994):** Adverse effects of blood transfusion. Transfusion Therapy; Guidelines For Practice, American Association of Blood Banks, Arlington, VA.
- Craig, R. Smith (1998):** Management of bleeding complications in Redo Cardiac operations. *Ann.Thorac.Surg.* **65**:52-8.
- Dahlbäck, B., Hildebrand, B. and Malm, J. (1990):** Characterization of functionally important domains in vitamin K-dependent protein S using monoclonal antibodies. *J.Biol.Chem.* **265**:8127-33.
- Dahlbäck, B. and Shen, I. (1994):** Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. *J.Biol.Chem.* **269**:18735-41.
- Dahlbäck, B. and Shen, I. and Xuhaue, H. (1997):** Synergistic cofactor function of factor V and Protein S to activated protein C in the inactivation of the factor VIIIa-factor IXa complex. *Thromb.Haemost.* **78**:1030-6.
- Dames, J. and Pepper, D. (1992):** Human vascular endothelial cells catabolizes exogenous glycosaminoglycans by a novel route. *Thromb.Haemost.* **67**:468-72.
- Davies, M.G. and Hgen, P.O. (1993):** The vascular endothelium. A new horizon. *Ann.Surg.* **218**:593-609.
- Davis, R. and Whittington, R. (1995):** Aprotinin: a review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery. *Drugs* **49**:954-83.

References

- Dehmer, G.J., Fisher, M., Tate, D.A., Teo, S. and Bonnem, E.M. (1995):** Reversal of heparin anticoagulation by recombinant platelet factor 4 in human. *Circulation* 91:2188-94.
- Deng, M.C., Wiedner, M., Erren, M. et al. (1995):** Arterial and venous cytokine response to cardiopulmonary bypass for low risk CABG and relation to hemodynamics. *Eur.J.Cardiothorac.Surg.* 9:22-9.
- Dietrich, W., Spannagl, M., Jochum, M. et al (1990):** Influence of high dose of aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. *Anaesthesiology* 73:1119-26.
- Dietrich, W., Spannagl, M., Schramm, W., Vog, W. and Richter, J.A. (1991):** The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass. *J.Thorac.Cardiovasc.Surg.* 102:505-14.
- Doolittle, R.F. (1994):** Fibrinogen and Fibrin. *Hemostasis And Thrombosis*, 3rd Edition, Vol. I. Churchill Livingstone, Edinburgh, Great Britain. Page 491-513.
- Donahue, S.G.and Buskard, N.A. (1996):** Recent developments in blood transfusion. *Medicine International* 24:56-60.
- Doyle, M. and Haley, P.E. (1993):** Meizothrombin: active intermediate formed during prothrombinase-catalyzed activation of prothrombin. *Methods Enzymol.* 222:299-312.
- Ebbling, L., Robertson, C., McNicol, A. and Garard, J. (1992) :**Rapid ultrastructural changes in the dense tubular system following platelet activation. *Blood* 80:718-23.
- Edward, J., Parfitt, A., Adam, B. et al. (1997):** A study of platelet activation during human cardiopulmonary bypass and the effect of S-nitrosoglutathione. *Thromb.Haemost.* 78:1516-9.

References

- Eldering, E., Citarella, F., Hack, C.E. et al (1996):** Modulation of contact system proteases by glycosaminoglycans-selective enhancement of the inhibition of factor XIa. *J.Biol.Chem.* **271**:12913-18.
- Elliott, M.J. (1993):** Ultrafiltration and modified ultrafiltration in pediatric open heart operations. *Ann.Thorac.Surg.* **56**:1518-22.
- Emeis, J.J. (1992):** Regulation of the acute release of tissue-type plasminogen activator from endothelium by coagulation activation products. *Ann.N.Y.Acad.Sci.* **667**:249-58.
- Erseinberg, P.R. (1991):** Endothelial cell mediators of thrombosis and fibrinolysis. *Coronary Artery Dis.* **2**:129-66.
- Esmon, C.T. and Fukudome, K. (1994):** Identification, cloning, and regulation of a novel endothelial cell protein C / activated protein C receptor. *J.Biol.Chem.* **269**:26486-92.
- Faber, V., Quentin, H., Breuer, B. et al. (1992):** Localization of a large heterodimeric proteoglycan with basement membrane proteins in cultured cells. *Eur.J.Cell.Biol.* **59**:37-43.
- Fitch, J., Rinder, C., Smith, B. and Rollins, S. (1995):** Terminal complement components produce platelet and leukocyte activation during stimulation by extracorporeal circulation. *Anesth.Analg.* **80**:15-22.
- Fosse, E., Moen, O., and Johnson, E. (1997):** Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. *Ann. Thorac. Surg.* **74**: 815-25.
- Frebelius, S., Hedin, U. and Swedenborg, J. (1994) :** Thrombogenicity of the injured vessel wall. Role of antithrombin and heparin. *Thromb.Haemost.* **71**:147-53.
- Gailani, D. and Broze, G.J. (1993):** Effects of glycosaminoglycans on factor XI activation by thrombin. *Blood Coagul. Fibrinolysis* **4**:15-20.

References

- Gram, J., Janetzko, T., Jespersen, J. and Bruhn, H.D. (1992):** Enhanced effective fibrinolysis following neutralization of heparin in open heart surgery increases the risk of post-surgical bleeding. *Thromb.Haemost.* **73**:241-45.
- Gurbuz, A.T., William, M.N., Pierce, C.A. and Watson, D.C. (1998):** Impact of ultrafiltration on blood use for atrial septal defect closure in infants and children. *Ann.Thorac.Surg.* **65**:1105-9.
- Hackeng, T.M., Hessing, M. et al. (1993):** Protein S binding to human endothelial cells is required for expression of cofactor activity for activated protein C. *J.Biol.Chem.* **268**:3993-4000.
- Hamilton, S.M. (1997):** Special issues in transfusion medicine. *Clin.Lab.Med.* **42**:743-57.
- Handin, R.I. and Cohen, H.J. (1992):** Purification and binding properties of human platelet factor 4. *J.Biol.Chem.* **351**:4273-82.
- Hantgon, R., Endenburg, S., Caverio, I., Marguerie, G. et al. (1992):** Inhibition of platelet adhesion to fibrinogen in flowing whole blood by Arg-Gly-Asp and fibrinogen α -chain carboxy terminal peptides. *Thromb.Haemost.* **68**:694-700.
- Harker, G.G. (1993):** The effects of surgery with cardiopulmonary bypass on alveolar capillary barrier function in man. *Ann.Thorac.Surg.* **80**:133-42.
- Haslam, P.L., Townsend, P.J. and Branthwaite, M.A. (1990):** Complement activation during cardiopulmonary bypass. *Anaesthesia* **53**:22-26.
- Heal, J.M. and Blumberg, N. (1993):** The rationale for limiting recipient exposure to homologous transfusion. *Transfusion* **30**:291-97.
- Heiss, K.F., Petit, B. and Gilley, R.E. (1987):** Ultrafiltration during open heart surgery in chronic renal failure. *Scand J Thorac Cardiovasc Surg.*

References

- Henderson, L.W. (1979):** Pre versus post dilution hemofiltration. *Clin.Nephrol.* 11:120-28.
- Hevessy, Z., Haramura, G., Zoltan, B. et al (1996):** Promotion of the crosslinking of fibrin and α_2 -antiplasmin by platelets. *Thromb.Haemost.* 75:161-7.
- Hoppensteadt, D.A., Wallenga, J.M., Fareed, J. et al (1995):** TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. *Thromb.Res.* 77:175-83.
- Isbister, J. (1994):** Adverse reactions to plasma and plasma components. *Transfusion* 42:27-30.
- Jain, U., Wallis, D.E. and Moran J.F. (1994):** Significance of electrocardiographic ST elevation during coronary bypass surgery. *Anesth.Analg.* 78:638-44.
- Jandrut-Perrus, M., Huisse, M., Krstenansky et al. (1992):** Effect of hirudin carboxy-terminal peptide on the interaction of thrombin with platelets. *Thromb.Haemost.* 66:300-305
- John, I., Thompson, S.G., Kiemast, J. and Pyke, S.D. (1994):** Baseline associations of hemostatic factors with extent of coronary risk factors in patient undergoing coronary artery bypass graft surgery. *Anesth.Analg.* 78:638-43.
- Journois, D., Pouard, P., William, J. et al. (1994):** Hemofiltration during cardiopulmonary bypass in pediatric cardiac surgery. *Anesthesiology* 81:1181-89.
- Kansas, G.S. (1996):** Selectins and their ligands. Current concepts and controversies. *Blood* 88:3259-87.

References

Kaplan, A.P., Reeigari, S.R. and Silverberg, M. (1995): Assembly of the human plasma kinin-forming cascade along the surface of vascular endothelial cells. *Int.Arch.Allergy Immunol.* **107**:93-5.

Kern, F., Morana, N., Sears, J. and Paul, H. (1992): Coagulation defects in neonates during cardiopulmonary bypass. *Ann.Thorac.Surg.* **54**:541-6.

Kestin, A.S., Valeri, C.R., Khuri, S.F. et al (1995): The platelet function defect of cardiopulmonary bypass. *Blood* **82**:107-17.

Kinlough, R., Packham, M., Perry, D. et al. (1992): Lack of stability of aggregates after thrombin induced reaggregation of thrombin degranulated platelets. *Thromb.Haemost.* **67**:453-7.

Kirklin, J.K., Westaby, S., Blackstone, E.H. et al. (1996): Complement and damaging effects of cardiopulmonary bypass. *J.Thorac.Cardiovasc.Pharmacology* **27**:26-30.

Koppelman, S.J., van'tVeer, C., Sixma, J.J. and Bouma, B.N. (1995): Synergistic inhibition of the intrinsic factor X activation by protein S and C_{4b}-binding protein. *Blood* **86**:2653-62.

Kumar, R., Béguin, S., Hemker, H.C. (1994): The influence of fibrinogen and fibrin on thrombin generation—evidence for feedback activation of the clotting system by clot bound thrombin. *Thromb.Haemost.* **72**:713-21.

References

- Lefer, A.M., Tsao, P.S. and Max, L. (1991):** Role of endothelial dysfunction in the pathogenesis of reperfusion injury after myocardial ischemia. *FASEBJ.* 5:2029-34.
- Lehot, J.J., Villard, J., Piriz, H. et al. (1994):** Hemodynamic and hormonal responses to hypothermic and normothermic cardiopulmonary bypass. *J.Cardiothorac.Vasc.Anesth.* 10:132-9.
- Levi, M., Roen, D., Kamp, A. et al (1993):** Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo. *Thromb.Haemost.* 69:141-146.
- Lindhout, T., Blezer, R., Schoen, P. et al.(1992):** The fibrinolytic inhibitor PAI-1 mediated an adhesive interaction with human tumor cells. *Blood* 82:1105-17.
- Lindhout, T., Franssen, J. and Willems, G. (1995):** Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor. *Thromb.Haemost.* 74:910-17.
- Lukens, W.B., Sally, V. and Rudmann, T. (1996):** Textbook Of Blood Banking and Transfusion Medicine. 3rd ed. Page 423
- Lupu, C., Dennehy, U., Kakkar, V.V. and Scully, M.F. (1995):** Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. *Arterioscler.Thromb.Vasc.Biol.* 15:20551-61.
- Macfarlane, R. (1977):** Hemostasis: introduction. *Br.Med.Bull.* 33:183.
- Mann, K.G., Krishnaswamy, S. and Lawson, J.H. (1992):** Surface-dependent hemostasis. *Semin.Hematol.* 29:213-26.
- Mann, K.G., Long, G.L. and Lu, D.S. (1996):** Comparison of activated protein C protein S-mediated inactivation of human factor VIII and factor V. *Blood* 87:4708-17.

References

- Marti, F., Munoz, J., Peiro, M., Bertran, E. et al. (1995):** Higher cytotoxic activity and increased levels of IL-1 beta and TNF-alpha in patients undergoing cardiopulmonary bypass. *Am.J.Hematol.* **49**:237-9.
- Marx, G., Korner, G., Mou, X. and Gorodetsky, R. (1993):** Packaging zinc, fibrinogen and factor XIII in platelet α -granules. *Cell.Physiol.* **156**:437-42.
- Mazer, C.D., Hornstein, A. and Freedman, J. (1995):** Platelet activation in warm and cold heart surgery. *Ann.Thorac.Surg.* **59**:1481-86.
- McCachren, S.S., Diggs, J., Wembeerg, J.B. and Dittman, W.A. (1991):** Thrombomodulin expression by human blood monocytes and by human synovial tissue lining macrophages. *Blood* **78**:3128-36.
- Meloni, F., Gustafson, E. and Schimaier, A. (1992):** High molecular weight kininogen binds to platelets by its heavy and light chains and when bound has altered to kallikrein cleavage. *Blood* **79**:1233-44.
- Menasche, P., Haydar, S., Peynet, J., Merva, R. et al. (1994):** A potential mechanism of vasodilatation after warm heart surgery. Temperature-dependent release of cytokines. *J.Thorac.Cardiovasc.Surg.* **107**:293-99.
- Menichetti, A., Tritapepe, L., Ruvalo, G. et al. (1996):** Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs. tranexamic acid vs. epsilon amino caproic acid. *J.Cardiovasc.Surg.* **37**:401-7.
- Merel, W., Stam, J., Cornelis, V. et al. (1996):** The interaction of protein S with the phospholipid surface is essential for the activated protein C-independent activity of protein S. *Thromb.Haem.* **75**:397-403.
- Mertens, G., Cassiman, J., Van den Berge, H. and David, G. (1992):** Surface heparan sulfate proteoglycans from human vascular endothelial cells. *J.Biol.Chem.* **267**:20435-43.

References

- Michael, J. and Marsh, N. (1997):** Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin. *Thromb.Haemost.* **78**:1021-26.
- Mohri, W. and Ohkubo, T. (1993):** Effects of hybrid peptide analogues to receptor recognition domains on α - and β -chains of human fibrinogen on fibrinogen binding to platelets. *Thromb.Haemost.* **69**:490-5.
- Moore, S.B. (1997):** Hepatitis C: progressive problem. *Transfusion Science* **26**(2): 89-99.
- Morel, D.R., Lowenstein, E., Ngayenduy, T. et al. (1990):** Acute pulmonary vasoconstriction and thromboxane release during protamine reversal of heparin anticoagulation. *Circ.Res.* **62**:905-15.
- Morgenstern, E. (1995):** The formation of compound granules from different types of secretory organelles in human platelets. *Eur.J.Cell.Biol.* **43**:273-82.
- Mosesson, M.W. (1990):** Fibrin polymerization and its regulatory role in hemostasis. *J.Lab.Clin.Med.* **116**:8-17.
- Mosesson, M.W., Siebenlist, K.R., DiOrio, J.P. et al. (1996):** The role of fibrinogen D domain intermolecular association sites in the polymerization of fibrin and fibrinogen (γ 275 Arg-Cys) *J.Clin.Invest.* **96**:1053-58.
- Mosesson, M.W., Siebenlist, K.R., Voskuilen, M. and Willem, N. (1998):** Evaluation of the factors contributing to fibrin-dependent plasminogen activation. *Thromb.Haemost.* **79**:796-801.
- Mössinger, H. and Dietrich, W. (1998):** Activation of hemostasis during cardiopulmonary bypass and pediatric aprotinin dosage. *Ann.Thorac.Surg.* **65**:45-51.
- Nishioka, J., Hayashi, T. and Suzuki, K. (1996):** The Gla(26) residue of protein C is required for the binding of protein C to thrombomodulin and endothelial cell protein C receptor. *Thromb.Haemost.* **75**:275-82.

References

- Nurden, P. (1997):** Bidirectional trafficking of membrane glycoproteins following platelet activation in suspension. *Thromb.Haemost.* **78**:1305-15.
- Nurden, P. and Nurden, A.T. (1993):** A review of the role of platelet membrane glycoproteins in the platelet-vessel wall inactivation. *Ballieres Clinical Hematology* **6**:653-90.
- Nurden, P., Heilmann, E., Paponneau, A. and Nurden, A.T. (1994):** Two way trafficking of membrane glycoproteins on thrombin-activated human platelets. *Sem.Hematol.* **31**:240-50 .
- Oleksowicz, L., Zukerman,D., Isaacs, R., Dutcher, J. et al. (1994):** Effects of interleukin2 administration on platelet function in cancer patients. *Am.J.Hematol.* **45**:224-31.
- Ordinas, A., Escolor, G. and White, J.G. (1993):** Ultrastructure of platelets and platelet surface interactions. *Arterioscler.Thromb.* **13**:791-99.
- Parkinson, J.F., Bang, N.U. and Garcia, J.N. (1991):** Recombinant human thrombomodulin attenuates the inflammatory response of thrombin-stimulated endothelial cells. *Thromb.Haemost.* **65**:825-32.
- Paul, G.G., and Michael, J.R. (1996):** Advances in cardiopulmonary bypass circuit. *J.Cardiovasc.Pharmacology* **27**:22-29.
- Peterson,L.C., Foster, D.C., Blumberg, H. et al. (1996):** Inhibitory properties of a novel human protease inhibitor homologous to tissue factor pathway inhibitor. *Biochemistry* **35**:266-72.
- Philips, M., Juul, A., Selmen, J. et al. (1992):** A specific immunologic assay for functional plasminogen activator inhibitor I in plasma standardized measurements of the inhibitors and related parameters in the patients with thromboembolic disease. *Thromb.Haemost.* **68**:486-94.

References

- Picot, T., Maugeri, N., Piccardoni, P. et al. (1994):** Increased platelet thromboxane A₂ generation in the presence of activated polymorphonuclear leukocytes. *Blood* **82**:447-51.
- Polgar, J., Lerant, I., Muszbek, L. and Machovich, R. (1986) :** Thrombomodulin inhibits the activation of factor XIII by thrombin. *Thromb.Res.* **43**:585-95.
- Rao, M., Rapaport, S. and Hoang, D. (1993):** Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa. *Blood* **81**:2600-7.
- Ratnoff, B., Long, L. and Stern, D. (1993):** Surface mediated defenses against injury. *Clin.Exp.Immunol.* **94**:320-31.
- Rawala, R., Ahmad, S., Monroe, D. et al. (1992):** Role of carboxyglutamic acid residues in the binding of factor IXa to platelets and in factor X activation. *Blood* **79**:398-405.
- Ray, M.J., Marsh, N.A. and Hawson, G.T. (1994):** Relationship of fibrinolysis and platelet function to bleeding after cardiopulmonary bypass. *Blood Coag.Fibrinol.* **5**:679-85.
- Rezaie, A.R. and Esmon, C.T. (1995):** Tryptophane 231 and 234 in protein C report the Ca(2+) dependent conformational change required for activation by the thrombin-thrombomodulin complex. *Biochemistry* **34**:12221-26.
- Rezaie, A.R., Cooper, S.T., Church, F.C. and Esmon, C.T. (1995):** Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex. *J.Biol.Chem.* **270**:25336-42.
- Rinder, C.S., Goal, D., Student, L.A., and Smith, B.R. (1994):** Platelet-leukocyte activation and modulation of adhesion receptors in pediatric patients with congenital heart disease undergoing cardiopulmonary bypass. *J.Thorac.Cardiovasc.Surg.* **107**:280-88.

References

- Robinson, R., Worfol, K. and Tracy, P. (1992):** Endotoxin enhances the expression of monocyte prothrombinase activity. *Blood* 79:406-16.
- Römisch, J. and Pâques, E.P. (1991):** Annexins: calcium-binding proteins of multifunctional importance. *Med.Microbiol.Immunol.* 180:109-19.
- Rosenfeld,R., Kuo,A., Hirsh, J. et al. (1992):** Heparin enhances active site-dependent binding of tissue-type plasminogen activator to endothelial cells. *Blood* 80:1486-95.
- Rosina, R.C. and Hoofnagle, J.H. (1992):** Type D (delta) hepatitis. *J.A.M.A.* 361:132-37.
- Ross, M.U. (1998):** Effects of cardiopulmonary bypass and use of modified ultrafiltration. *Ann.Thorac.Surg.* 65:535-39.
- Royston, D. (1992):** High-dose aprotinin therapy: a review of the first five years experience. *J.CardiThorac.Vasc.Anesth.* 6:76-100.
- Ruf, A., Maras, A. and Morgenstern, E. (1992):** Contact-induced neutrophil activation by platelets in human cell suspension and whole blood. *Blood* 80:1238-46.
- Ryan, U.S. and Rubanyi,G.M. (1992):** Endothelial regulation of vascular tone. *Circulation* 86:218-25.
- Ryhanen, P., Hena, E., Hollmen, A. and Nuutinen, L. (1990):** Changes in peripheral blood leukocyte counts,lymphocyte subpopulations, and in vitro transformation after heart valve replacement. *J.Thorac.Cardiovasc.Surg.* 97:259-99.
- Saito,H. (1991):** Normal Hemostatic Mechanisms In Disorders of Hemostasis. Editors: Ratnoff, O. and Forbes,C. Saunders,W.
Page 18.

References

- Scully, M., Toh, C., Manuel, R. et al. (1993):** Activation of protein C and its distribution between its inhibitors, protein C inhibitors, and α_2 macroglobulin, in patients with disseminated intravascular coagulation. *Thromb. Haemost.* **69**:448-53.
- Sedlmayr, P., Blaschitz, A., Tiran, A. and Dohr, G. (1995):** Platelets contain interleukin-1 alpha and beta which are detectable on the cell surface after activation. *J. Immunol.* **42**:209-14.
- Seeper, J.M., Nicholls, M.D. and Snyder, E.L. (1991):** Transfusion morbidity and mortality. *Anaesth. Intens. Care* **21**:132-39.
- Sheretz, R.J., Russell, B.A. and Reuman, P.D. (1992):** Transfusion associated hepatitis. Mortality and morbidity. *Arch. Intern. Med* **144**:1579-84.
- Shima, M., Scandella, D., Yoshioka, A. et al. (1993):** A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C-2 domain inhibit factor VIII binding to vWF and to phosphatidyle serine. *Thromb. Haemost.* **68**:240-46.
- Silverberg, M. and Kaplan, P. (1992):** Enzymatic activities of activated and zymogen forms of human factor XII. *Blood* **78**:60-64.
- Silverstein, R. and Febbraio, M. (1992):** Identification of lysosome-associated membrane protein-2 as an activation dependent platelet surface glycoprotein. *Blood* **80**:1470-75.
- Simionescu, M. (1993):** Endothelial cell biology in health and disease. *Ann. Thorac. Surg.* **55**:630-9.
- Solem, J.O., Tengborn, L., Steen, S. and Luhrs, C. (1990):** Cell saver versus hemofilter for concentration of oxygenator blood after cardiopulmonary bypass. *Thorac. Cardiovasc. Surg.* **65**:42-47.

References

- Stam, J.G., van't Veer, C., Bertina, R.M. et al. (1996)** :The interaction of protein S with the phospholipid surface is essential for the activated protein C independent activity of protein S. *Thromb.Haemost.* **76**:397-403.
- Stearns, K., Kurosawa, S., Mollica, J. et al. (1996)**: The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. *Proc.Natl.Acad.Scie. USA* **93**:10212-16.
- Steinberg, J.B., Kapelanki, D.P., Olson, J.D. and Weller, J.M. (1994)**: Cytokine and complement levels in patients undergoing cardiopulmonary bypass. *J.Thorac.Cardiovasc.Surg.* **161**:1008-16.
- Stern, D.M., Koedam, J.A., Koppelman, S.J. et al. (1994)**: von Willebrand factor as a regulator of intrinsic factor X activation. *J.Lab.Clin.Med.* **123**:585-92.
- Sun, J., Salem, H.H. and Bird, P. (1992)**: Nucleolus and cytoplasmic localization of annexin V. *FEBSLett* **314**:425-31.
- Thaler, M., Shaniss, A., Orgad, S. et al. (1994)**: The role of blood from HLA-homozygous donor in fatal transfusion-associated graft-versus-host disease after open heart disease. *N.Engl.J.Med.* **321**:25-28.
- Thomas, B., Michele, M. and André, H. (1997)**: Anticoagulant properties of the vascular endothelium. *Thromb.Haemost.* **77**:408-23.
- Tollefsen, D.N. (1995)**: Insight into the mechanism of action of heparin cofactor II. *Thromb.Haemost.* **74**:1209-14.
- Utely, J.R. (1990)**: Historical perspectives and basic pathophysiology. *Semin.Thorac.Cardiovasc.Surg.* **2**:292-300.
- Van Heerde, W.L., Poort, S. et al. (1994)**: Binding of recombinant annexin V to endothelial cells. *Biochem.J.* **302**:300-11.

References

- Velosa, D., Smith, J., Demy, S. and Cosgriff, T. (1992):** Structure, kinetics, and function of human and rhesus plasma prekallikrein are similar. *Thromb.Haemost.* **68**:526-33.
- Wagner, W. and Hubbel, J. (1992):** ADP receptor antagonists and converting enzyme systems reduce platelets deposition onto collagen. *Thromb.Haemost.* **67**:461-67.
- Walker, R.H. (1995):** Technical Manual. American Association of Blood Banks. Arlington, V.A.
- Wang, M.J., Chiu, I.S. and Hiss, C.M. (1996):** Efficacy of ultrafiltration in removing inflammatory mediators during pediatric cardiac operations. *Ann.Thorac.Surg.* **61**:651-56.
- Waters, A.A. (1993):** Reproduction of transfusion-related acute lung injury in an ex-vivo lung model. *Blood* **86**:1438-44.
- Weidmer, T. and Sims, P.J. (1991):** Participation of protein kinases in complement C₅b-9-induced shedding of platelet plasma membrane vesicles. *Blood* **78**:2880-6.
- Weiler, J.M., Glhaus, M.A., Carter, J.G. et al. (1992):** A prospective study of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery. *J.Allergy Clin.Immunol.* **85**:713-15.
- Wencel-Drake, J.D. (1991) :** Platelet secretion and receptor cycling. *Blood Cells* **17**:486-95.
- Wheeldon, D.R. (1988):** Blood conservation during cardiopulmonary bypass-autologous transfusion, cell saving and hemofiltration. *Cardiopumony Bypass – Principles and Managment.* Editor: Taylor, K.M. Baltimore, Williams & Wilkins. Page 289-311.
- Widmann, F.K. (1995):** Prevention of HLA alloimmunization with leukocyte-poor packed red cells and role of radiation gamma. *Transplantation Transfusion Med.Reviews* **10**:1-17.

References

- Widmann, F.K. (1996):** Standards For Blood Banks and Transfusion Services. 15th Edition. American Association of Blood Banks, Arlington, Va.
- Williams, J.W., Ernest, B., Allan, J.E. and Marshall, A.L. (1990):** Hemostasis. Hematology Textbook. 4th Edition. Page 1322.
- Zoelkner, H., McGrath, M., Hamilton, J., et al. (1993):** Cytokine regulation of the synthesis of plasminogen activator inhibitor-2 by human vascular endothelial cells. *Thromb.Haemost.* **69**:135-40.